Novartis AG ADR (NVS)vsTiziana Life Sciences Ltd (TLSA)

NVS

Novartis AG ADR

NYSE

$147.85

+3.44%

HEALTHCARE · Cap: $280.79B

TLSA

Tiziana Life Sciences Ltd

NASDAQ

$1.28

+1.59%

HEALTHCARE · Cap: $159.06M

⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates -1576567% more annual revenue ($56.67B vs $-3.60M). NVS leads profitability with a 24.7% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).

NVS

Buy

out of 100

Grade: C-

Growth: 4.0Profit: 9.0Value: 3.3Quality: 5.5

Piotroski: 4/9Altman Z: 1.96

TLSA

Avoid

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 5.0

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NVSSignificantly Overvalued (-52.2%)

Margin of Safety

-52.2%

Fair Value

$109.78

Current Price

$147.85

$38.07 premium

UndervaluedFair: $109.78Overvalued

Intrinsic value data unavailable for TLSA.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVS5 strengths · Avg: 9.0/10

Market CapQuality

$280.79B10/10

Mega-cap, among the largest globally

Return on EquityProfitability

30.8%10/10

Every $100 of equity generates 31 in profit

Profit MarginProfitability

24.7%9/10

Keeps 25 of every $100 in revenue as profit

Operating MarginProfitability

27.8%8/10

Strong operational efficiency at 27.8%

Free Cash FlowQuality

$2.87B8/10

Generating 2.9B in free cash flow

TLSA0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

NVS4 concerns · Avg: 3.0/10

Revenue GrowthGrowth

2.2%4/10

2.2% revenue growth

Altman Z-ScoreHealth

1.964/10

Grey zone — moderate risk

PEG RatioValuation

2.532/10

Expensive relative to growth rate

EPS GrowthGrowth

-11.6%2/10

Earnings declined 11.6%

TLSA4 concerns · Avg: 3.8/10

Price/BookValuation

16.0x4/10

Trading at 16.0x book value

Revenue GrowthGrowth

0.0%4/10

0.0% revenue growth

EPS GrowthGrowth

0.0%4/10

0.0% earnings growth

Market CapQuality

$159.06M3/10

Smaller company, higher risk/reward

Comparative Analysis Report

WallStSmart Research

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 24.7% and operating margin at 27.8%.

Bull Case : TLSA

TLSA has a balanced fundamental profile.

Bear Case : NVS

The primary concerns for NVS are Revenue Growth, Altman Z-Score, PEG Ratio.

Bear Case : TLSA

The primary concerns for TLSA are Price/Book, Revenue Growth, EPS Growth.

Key Dynamics to Monitor

NVS carries more volatility with a beta of 0.52 — expect wider price swings.

NVS is growing revenue faster at 2.2% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NVS scores higher overall (51/100 vs 16/100), backed by strong 24.7% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Tiziana Life Sciences Plc, a clinical-stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the UK.

Compare with Other DRUG MANUFACTURERS - GENERAL Stocks

NVS vs LLY NVS vs JNJ NVS vs ABBV NVS vs AZN NVS vs MRK TLSA vs LLY TLSA vs JNJ TLSA vs ABBV TLSA vs AZN TLSA vs MRK

Want to dig deeper into these stocks?

Full NVS Analysis →Full TLSA Analysis →